|
MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
More... |
| All times are GMT -7. The time now is 11:21 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021